THOUSAND OAKS, Calif.,
May 28, 2015 /PRNewswire/ -- Amgen
(NASDAQ: AMGN) today announced the creation of a catalog of
qualified tools and reagents available to academic institutions to
help further research and advance basic discoveries in biology, as
well as deepen relationships with academic institutions. This
catalog and its associated materials are called the Amgen
Biology-Enabling Resource (AmBER).
AmBER is comprised of more than 1,000 elements and includes
small molecules, peptides, antibodies and recombinant proteins,
engineered cell lines, and genetically-engineered mice. These are
tools created to support discovery activities throughout Amgen's
history and have been extensively validated in most cases.
"We see AmBER as an important contribution in our effort to
connect with the academic community and to help advance scientific
discovery," said Alexander Kamb,
Ph.D., senior vice president of Discovery Research at Amgen. "AmBER
will allow Amgen to further expand relationships around innovative
biology and medicine and enhance research literature quality by
providing qualified materials."
Amgen scientists and staff assembled these materials and have
organized pertinent information into a searchable catalog. This
catalog is available to designated institutions. Amgen will
provide the materials on request as a donation to the cause of
basic science—with no claim to ownership of intellectual property
to discoveries that may ensue. As specific materials are depleted,
Amgen anticipates others will be added so that AmBER continues as
an evolving resource for academics.
For inquiries about the AmBER project, please email
amber.research@amgen.com.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its biologics manufacturing expertise to strive for solutions that
improve health outcomes and dramatically improve people's lives. A
biotechnology pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
Forward-Looking Statements
This news release contains
forward-looking statements that involve significant risks and
uncertainties, including those discussed below and others that can
be found in our Form 10-K for the year ended Dec. 31, 2014, and in any subsequent periodic
reports on Form 10-Q and Form 8-K. Amgen is providing this
information as of the date of this news release and does not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. The
Company's results may be affected by our ability to successfully
market both new and existing products domestically and
internationally, clinical and regulatory developments (domestic or
foreign) involving current and future products, sales growth of
recently launched products, competition from other products
(domestic or foreign) and difficulties or delays in manufacturing
our products. In addition, sales of our products are affected
by reimbursement policies imposed by third-party payers, including
governments, private insurance plans and managed care providers and
may be affected by regulatory, clinical and guideline developments
and domestic and international trends toward managed care and
healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and
others' regulations and reimbursement policies may affect the
development, usage and pricing of our products. Furthermore,
our research, testing, pricing, marketing and other operations are
subject to extensive regulation by domestic and foreign government
regulatory authorities. We or others could identify safety,
side effects or manufacturing problems with our products after they
are on the market. Our business may be impacted by government
investigations, litigation and product liability claims. If
we fail to meet the compliance obligations in the corporate
integrity agreement between us and the U.S. government, we could
become subject to significant sanctions. Further, while we
routinely obtain patents for our products and technology, the
protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors.
We depend on third parties for a significant portion of our
manufacturing capacity for the supply of certain of our current and
future products and limits on supply may constrain sales of certain
of our current products and product candidate development. In
addition, we compete with other companies with respect to some of
our marketed products as well as for the discovery and development
of new products. Discovery or identification of new product
candidates cannot be guaranteed and movement from concept to
product is uncertain; consequently, there can be no guarantee that
any particular product candidate will be successful and become a
commercial product. Further, some raw materials, medical
devices and component parts for our products are supplied by sole
third-party suppliers. Our efforts to integrate the
operations of companies we have acquired may not be
successful. We may experience difficulties, delays or
unexpected costs and not achieve anticipated benefits and savings
from our recently announced restructuring plan. Our business
performance could affect or limit the ability of the Amgen Inc.
Board of Directors to declare a dividend or our ability to pay a
dividend or repurchase our common stock.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, (805) 447-3008
(media)
Arvind Sood, 805-447-1060
(investors)
Logo -
http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-launches-program-to-further-advance-basic-biology-research-300090477.html
SOURCE Amgen